Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide.
Flawless balance sheet with limited growth.
Share Price & News
How has Masimo's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MASI's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: MASI exceeded the US Medical Equipment industry which returned 13.5% over the past year.
Return vs Market: MASI exceeded the US Market which returned 8.5% over the past year.
Price Volatility Vs. Market
How volatile is Masimo's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StShareholders Are Raving About How The Masimo (NASDAQ:MASI) Share Price Increased 556%
2 weeks ago | Simply Wall StWhy You Should Like Masimo Corporation’s (NASDAQ:MASI) ROCE
4 weeks ago | Simply Wall StA Rising Share Price Has Us Looking Closely At Masimo Corporation's (NASDAQ:MASI) P/E Ratio
Is Masimo undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MASI ($226.99) is trading above our estimate of fair value ($159.73)
Significantly Below Fair Value: MASI is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MASI is poor value based on its PE Ratio (57.6x) compared to the Medical Equipment industry average (48.1x).
PE vs Market: MASI is poor value based on its PE Ratio (57.6x) compared to the US market (15.8x).
Price to Earnings Growth Ratio
PEG Ratio: MASI is poor value based on its PEG Ratio (4.8x)
Price to Book Ratio
PB vs Industry: MASI is overvalued based on its PB Ratio (9.8x) compared to the US Medical Equipment industry average (3.8x).
How is Masimo forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MASI's forecast earnings growth (11.9% per year) is above the savings rate (2.2%).
Earnings vs Market: MASI's earnings (11.9% per year) are forecast to grow slower than the US market (22.1% per year).
High Growth Earnings: MASI's earnings are forecast to grow, but not significantly.
Revenue vs Market: MASI's revenue (9% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: MASI's revenue (9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MASI's Return on Equity is forecast to be low in 3 years time (15.7%).
How has Masimo performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MASI has high quality earnings.
Growing Profit Margin: MASI's current net profit margins (21.7%) are lower than last year (22.5%).
Past Earnings Growth Analysis
Earnings Trend: MASI's earnings have grown by 12.7% per year over the past 5 years.
Accelerating Growth: MASI's earnings growth over the past year (7.2%) is below its 5-year average (12.7% per year).
Earnings vs Industry: MASI earnings growth over the past year (7.2%) underperformed the Medical Equipment industry 7.2%.
Return on Equity
High ROE: MASI's Return on Equity (16.9%) is considered low.
How is Masimo's financial position?
Financial Position Analysis
Short Term Liabilities: MASI's short term assets ($980.2M) exceed its short term liabilities ($157.3M).
Long Term Liabilities: MASI's short term assets ($980.2M) exceed its long term liabilities ($64.0M).
Debt to Equity History and Analysis
Debt Level: MASI is debt free.
Reducing Debt: MASI has no debt compared to 5 years ago when its debt to equity ratio was 38.6%.
Debt Coverage: MASI has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: MASI has no debt, therefore coverage of interest payments is not a concern.
What is Masimo's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MASI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MASI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MASI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MASI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MASI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Joe Kiani (54yo)
Mr. Joseph E. Kiani, also known as Joe, founded Masimo Corporation in 1989 and has been its Chairman and Chief Executive Officer since 1989. Mr. Kiani serves as the Chairman and Chief Executive Officer of ...
CEO Compensation Analysis
Compensation vs Market: Joe's total compensation ($USD15.00M) is about average for companies of similar size in the US market ($USD11.58M).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
|Executive VP of Finance & CFO||2.67yrs||US$1.91m||no data|
|Chief Operating Officer||1.08yrs||US$4.23m||no data|
|Chairman of Scientific Advisory Board||no data||US$369.89k||0.12% $14.9m|
|Executive VP||7.17yrs||US$1.92m||0.012% $1.4m|
|Executive Vice President of Operations & Clinical Research||1.08yrs||US$1.97m||0.025% $3.0m|
|Chief Accounting Officer & Senior VP of Finance||5.33yrs||no data||0.0019% $220.5k|
|Executive VP & Chief Information Officer||18.17yrs||US$1.49m||0.14% $16.5m|
|Vice President of Business Development & Investor Relations||11yrs||no data||no data|
|President of Worldwide Sales||9.33yrs||US$1.78m||0.023% $2.7m|
Experienced Management: MASI's management team is seasoned and experienced (6.3 years average tenure).
|Chairman of Scientific Advisory Board||no data||US$369.89k||0.12% $14.9m|
|Independent Director||6.17yrs||US$274.89k||0.0080% $947.5k|
|Independent Director||1.42yrs||US$259.26k||0.0024% $287.2k|
|Independent Director||1.83yrs||US$262.39k||0.0024% $287.2k|
|Independent Director||4.5yrs||US$274.89k||0.014% $1.7m|
|Independent Director||3.67yrs||US$277.39k||0.0080% $947.5k|
Experienced Board: MASI's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Masimo Corporation's company bio, employee growth, exchange listings and data sources
- Name: Masimo Corporation
- Ticker: MASI
- Exchange: NasdaqGS
- Founded: 1989
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$11.918b
- Shares outstanding: 54.12m
- Website: https://www.masimo.com
Number of Employees
- Masimo Corporation
- 52 Discovery
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MASI||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Aug 2007|
|3M4||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Aug 2007|
|0JZ2||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Aug 2007|
|MASI *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Aug 2007|
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain’s electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. Additionally, the company offers Trace, a patient data visualization and reporting software for Masimo Root and Radical-7 monitors. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, home care providers, long term care facilities, veterinarians, and consumers. Masimo Corporation was founded in 1989 and is headquartered in Irvine, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/06 02:10|
|End of Day Share Price||2020/06/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.